The cytochrome P450 (CYP) enzyme system is involved in the metabolism and elimination of numerous widely used drugs. The capacity of this system varies from one person to another, leading to variable drug excretion rates and intersubject differences in the final serum drug concentrations. For this reason, therapeutic response and side-effects vary widely between patients treated with the same dose of drug. The intersubject variability in metabolic rate is largely determined by genetic factors. Some CYP enzymes, including CYP2D6 and CYP2CI9, are genetically polymorphic. Several mutant alleles have been described. Environmental factors such as smoking, diet and co-administration of medications might also influence the CYP enzyme activity. By the use of genotyping or phenotyping methods every individual can be classified as either a poor, an intermediate, an extensive or an ultrarapid metabolizer. If this could be performed prior to drug therapy, the knowledge could be applied to drug selection and dose adjustment in order to reach therapeutic serum drug levels.
TABLE 1. Cytochrome P450 (CYP) nomenclature system after the letter.I-' The nomenclature system is depicted in Table I .
At least 74 CYP gene families, of which 14 are ubiquitous in all mammals, have been described so far. 1 The enzymes belonging to the families CYPI, CYP2 and CYP3 catalyse the oxidative biotransformation of exogenous compounds, including many drugs, (pro)carcinogens, (pro)mutagens and alcohols. The other CYP families are involved in the metabolism of endogenous substances, such as fatty acids, prostaglandins and steroid and thyroid hormones." Table 2 shows some CYP enzymes that are relevant for The most important elimination pathway for lipophilic drugs is cytochrome P450 (CYP) (EC 1.14.14.1)-dependent oxidation. CYP mediates biotransformation to polar metabolites, which can be excreted by the kidneys. The human hepatic CYP system consists of over 30 related isoenzymes with different, sometimes overlapping, substrate specificities. The CYP enzymes have been classified in a systematic way on the basis of their amino acid sequence. A standard nomenclature system, categorizing enzymes in gene families and subfamilies, has been developed.' Families are indicated by the abbreviation for cytochrome P450 (CYP), followed by an arabic number. Members of a family are at least 40% identical. Within a family, enzymes with greater than 55% sequence homology are included in the same subfamily. Subfamilies are indicated by a letter following the family number. Individual genes, coding for one specific isoenzyme, have a second arabic number drug metabolism and some clinically important substrates.
POLYMORPHIC DRUG METABOLISM

Genetic polymorphism
The metabolic capacity of the CYP enzyme system is not equal in all members of a population. As a result, the metabolic conversion and excretion rate of drugs vary between individuals, from extremely slow to ultrafast. For many drugs, four major phenotypes can be distinguished: poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers (EMs) and ultrarapid metabolizers (UMs).
The intersubject variability in metabolic rate is largely determined by genetic factors.V' A number of CYP enzymes are known to be genetically polymorphic. Mutant alleles carrying certain nucleotide substitutions, deletions, insertions or gene conversions are known, which may result in CYP enzymes with abnormal activity. Some mutants, the so-called null alleles, lead to enzyme deficiency or total absence of enzyme activity. This genetically determined variance in enzyme activity results in the different drug metabolism phenotypes.
CYP2D6
Of all CYP enzymes, the highly genetically polymorphic enzyme debrisoquine-4-hydroxylase, or CYP2D6, has been the most extensively studied. CYP2D6 is involved in the oxidative metabolism of more than 40 widely prescribed drugs ( Table 2 ). The gene that codes for the CYP2D6 enzyme has been localized to chromosome 22, where it forms part of the CYP2D gene cluster with two non-functional pseudogenes, termed CYP2D7P and CYP2D8P. 7 The CYP2D6 gene contains nine exons within a total of 4378 base pairs.
More than 50 different CYP2D6 alleles have so far been identified.f-? Their expanding number has led to agreements on a common nomen-Cytochrome P450 enzyme system 723 clature, which has recently been updated.!? The allelic variants are divided into subgroups, sharing the same characteristic mutation(s). The CYP2D6 allele subgroups, associated with absent, decreased, normal or increased enzyme activity, are listed in Table 3 . 9 ,11-27 Five to 10% of Caucasians lack CYP2D6 activity completely because of the inheritance of two mutant CYP2D6 null alleles. These subjects are classified as PMs, with an impaired metabolism of CYP2D6 substrates.P The majority of defective allelic variants of the CYP2D6 gene that give rise to the PM phenotype have now been identified. Up to 7% of Caucasians are UMs of CYP2D6 substrates, owing to the inheritance of alleles with duplication or amplification of functional CYP2D6 genes, causing an excessive amount of enzyme to be expressed.U-" The metabolic capacity of the rest of the population lies somewhere between the extremes. IMs have mutations on the CYP2D6 gene, which cause only a partial decrease in enzyme activity. Subjects who are either homozygous for the normal-functioning alleles, or heterozygous with one active and one defect allele, are classified as EMs. Among EMs, metabolic rate can range considerably. In subjects homozygous for the active alleles, CYP2D6 drugs are metabolized more efficiently than the heterozygous genotypes. The latter are more at risk for drug-drug interaction if two or more CYP2D6 drugs have to be administered concomitantly. In general, the drug metabolism phenotype is determined by the number of functional CYP2D6 genes present.S!'
In non-Caucasian populations, PM and UM phenotypes of CYP2D6 substrates may occur with different prevalences. In Orientals, for example, there are hardly any PMs and UMs « I %), but the frequency of the 1M phenotype is very high" In some African populations, prevalences of up to 29% for the UM phenotype have been reported.'! 
CYP2C19
A second CYP enzyme which exhibits genetic polymorphism is S-mephenytoin-hydroxylase, or CYP2C19. The enzyme catalyses the metabolism of some tricyclic antidepressants and barbiturates (see Table 2 ). In addition to the wild-type gene, three allelic variants are known, which are associated with the complete absence of CYP2Cl9 activity (see Table 3 ). 25 
CLINICAL CONSEQUENCES OF POLYMORPHIC DRUG METABOLISM
There are numerous case reports demonstrating that variations in CYP enzyme activity can lead to intersubject differences in therapeutic efficacy of drugs. 9 ,35,36,43 -45 In general, PM subjects, either genetically determined or drug-induced, will develop higher serum drug concentrations in comparison with EMs, causing an increased risk of suffering from concentration-dependent sideeffects when subjected to standard recommended doses. UM subjects, on the other hand, will not reach therapeutic serum concentrations upon treatment with standard doses. They may fail to respond to treatment, leading to false accusations of non-compliance. When the parent compound is a prodrug, which requires bioactivation by the enzyme to the active drug, the opposite effects can be observed in PMs and UMs. As individual differences in drug disposition could be compensated for in part by dose adjustment according to the metabolic capacity," determination of drug metabolism phenotypes prior to drug therapy seems useful. PM and UM subjects can thus be identified and drug selection and dosage could be tailored to these individual patients from the beginning, which will help avoid adverse reactions or therapeutic failure. 36 ,43,45 However, the clinical significance of a specific enzyme polymorphism for a specific drug is not always clear and depends on several factors. A substantial amount of the drug should be metabolized by the enzyme. When the affected pathway plays only a minor part in the overall elimination of the drug, or alternative excretion pathways are available, the effect of the polymorphism on metabolic rate, and therefore on clinical outcome, will be negligible. In addition, the resulting variability in elimination rate should have some clinical impact. This is the case with drugs having a narrow therapeutic range, i.e. when the toxic serum concentration is just above the therapeutic concentration.
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On the basis of these criteria, the frequency of use and the usually (life)long period ofpharmacotherapy, the polymorphism of CYP2D6 in particular seems to be of great clinical importance for tricyclic antidepressants, certain antipsychotics and cardiovascular cornpounds.l'v" Individual metabolic capacity could be estimated by either phenotyping or genotyping approaches. Phenotyping is accomplished by administration of a probe drug, known to be selectively metabolized by the CYP enzyme under study, followed by measurement of the metabolic ratio (the ratio of drug dosage or unchanged drug to metabolite in serum or urine). Phenotyping takes into account all internal and external factors influencing the activity of the specific enzyme, and it reveals drug-drug interactions or defects in the overall process of drug metabolism. However, the method has several drawbacks. The protocols of testing are rather complicated and, especially in the case of psychiatric patients, difficult to perform correctly. In addition, there are risks of adverse drug reactions.
Genotyping involves identification of defined genetic mutations on the CYP genes that give rise to the specific drug metabolism phenotype. By screening for genetic variants, an individual's drug metabolism phenotype can be characterized. Genotyping is simple to perform and provides results within 24 h, allowing for rapid intervention. The method just requires a small blood, tissue or urine sample, which can be taken at any time, and it is not affected by underlying diseases or by co-administration of drugs. Genotyping needs to be done only once in a lifetime.
GENOTYPING METHODS FOR IDENTIFICATION OF PM AND UM SUBJECTS CYP2D6
Poor metabolization caused by CYP2D6 enzyme deficiency may be detectable with close to 100% accuracy by screening for all known nonfunctional CYP2D6 alleles. 8 ,43,45 The CYP2D6 null alleles and their inactivating mutation(s) are listed in Table 3 . Most of these deficiencycausing mutations can be detected by fast and easy assays based on the well-known polymerase chain reaction (PCR), followed by restrictiondigestion.Pr" When there is no suitable restriction endonuclease available for detection of a specific mutation, as is the case with CYP2D6*6 for example, PCR products could be used also for dot-blotting, followed by hybridization with labelled allele-specific oligonucleotide probes."
Nearly every CYP2D6 null allele listed in Table  3 can be detected by one of these methods. However, it is unnecessary and impractical to carry out routine screening for so many mutations. In our hospital we perform genotyping for the three most common defect gene variants, i.e. CYP2D6*3, CYP2D6*4 and CYP2D6*5, in every patient before starting pharmacotherapy. This allows identification of at least 95% of PMs in the Caucasian population.t" Screening for the remaining null alleles is performed when poor metabolism appears to be present on the basis of the dose/concentration ratio and is not found in the three allelic variants mentioned above.
UM caused by CYP2D6 gene duplication can be detected by PCR-based methods as well. 49 ,5o The genomic organization of an allele with duplicate CYP2D6 genes is shown in Fig. I . With primer pair cyp17/cyp32, a 3'6-kb PCR fragment amplified from the 2D6-2D6 region is observed in subjects having duplicate genes. In addition, a 5·2-kb fragment from a 2D7-2D6 intergenic region should be obtained from every sample as an internal control of the PCR reaction. Amplification of a 3·2-kb fragment indicative of a 2D6-2D6 intergenic sequence by primer combination cyp207/cyp32 is performed as a control reaction. This assay yields product only in subjects with duplicate genes. The resulting PCR fragments are separated and detected in ethidium bromide-containing agarose gels. In the case of homozygosity, it is clear which CYP2D6 allelic variant has been duplicated. In heterozygotes, additional PCR assays, as depicted in Fig. I for genotype *1/*4, should be performed in order to identify the duplicated gene.?
CYP2C19
Poor metabolization caused by CYP2CI9 deficiency can be detected by genotyping only with a sensitivity of about 80% in Caucasians." By usinga PCR assay followed by restriction-digestion the non-functional *2 variant can be identified, accounting for 75% of CYP2C19 alleles in PMs genotyped." In the Oriental population, a second mutation, CYP2C19*3, was found in conjunction with *2, accounting for 100% of alleles in Oriental PMS. 26 In Caucasians this *3 allele is rare, just like the recently characterized allele CYP2C19*4.n Other mutations associated with CYP2CI9 deficiency are yet to be discovered.
CYP2C9
The allelic variants CYP2C9*2 and CYP2C9*3, probably leading to impaired metabolism of CYP2C9-depcndent drugs, can be detected by PCR and restriction-digestion. In Caucasians, allele frequencies of 12·5% and 8·5% are reported, respectively. 32 Further studies are required to assess to what extent CYP2C9 genetic polymorphism affects enzyme activity and metabolic rate.
The specificity of both CYP2D6 and CYP2C19 genotyping for determination of drug metabolism phenotypes is 100% when appropriate control reactions are built in." The presence of an allele with duplicate functional CYP2D6 genes, in addition to a normal c 17> 207> 2x2F> functioning allele, always results in ultrarapid metabolism of CYP2D6 drugs. Genotyping is not very laborious. Screening for the most common defective allelic variants of CYP2D6, CYP2Cl9 and CYP2C9 and for the CYP2D6 gene duplication could be done within 24 h at a cost of £ 18 each when performed as a routine assay.
CONCLUSION
It is the opinion of some physicians and medical scientists that genotyping should be performed routinely in each instance when the drug of choice is substrate for a polymorphic enzyme, especially when a close relationship between serum drug concentration and effect is demonstrated. 6 • 36 ,43.44 Alternatively, genotyping should be indicated when individuals demonstrate suboptimal response to drugs that are substrates for polymorphic enzymes. Genetic analysis of CYP2D6 and CYP2Cl9 gives a fairly good prediction of PM and UM metabolic phenotypes, and this information can be used for individualization and optimization of drug therapy. Dose adjustment or the selection of an alternative drug that is not substrate for the polymorphic enzyme will help to avoid therapeutic failure and wrong suspicion of noncompliance in VMs, and the development of side-effects in PMs. In the case of 1M and heterozygous EM phenotypes, the clinician should be aware of a higher risk of drug-drug interactions when taking co-medication.
There would be a considerable cost associated with screening all patients before starting pharmacotherapy. On the other hand, there will be a reduction in costs associated with toxic episodes or therapeutic failure and subsequent intervention. Overall, the cost could be neutral.
Some hospitals have implemented routine genotyping techniques, but the relevance of this practice has been the subject of much debate. For many drugs the clinical effect of polymorphic drug metabolism is not clear. Serious side-effects do not invariably occur in persons with elevated serum drug levels. Moreover, administration of drugs based on genotyping is no guarantee that appropriate serum drug levels are attained. Other CYP enzymes may be involved in the elimination of a drug, and nongenetic factors may also influence enzyme activity. To evaluate the contribution of genetic polymorphism to adverse drug reactions and to define the true relevance of genotyping in clinical Cytochrome P450 enzyme system 727 practice, controlled prospective studies using a multidisciplinary approach are necessary. Based on the evidence at hand, it is suggested that an appropriate practice would be genotyping, forewarning the physician that a patient is susceptible to an increased risk of side-effects, non-response or drug-drug interaction, in combination with monitoring the patient's progress regularly and determining serum levels of drugs at appropriate time intervals.
